Allsci

Published September 28, 2026 · Updated September 29, 2026

Finland's Kasvu secures EUR 30m Series A for non-hallucinogenic depression drug - AllSci

Read the full story at Allsci

Why it matters: Kasvu is attempting to reproduce the neuroplasticity associated with psychedelic compounds without triggering their hallucinogenic.